Breaking News
Ori Biotech Raises Over $100 Million in Series B Funding to Launch Innovative Cell and Gene Therapy Manufacturing Platform
Companies In This Post
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more
Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Kate Therapeutics, a next-generation gene therapy company, today emerged from stealth mode with a $51 […]
SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment
SciTech Development has announced it has closed a $2.73M funding round, led by several prominent […]
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics, a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced […]
RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications
RxLightning, creator of the industry’s first comprehensive platform for streamlining specialty medication access and affordability, […]
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, has announced an equity […]
VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics
VaxEquity, developing transformative RNA vaccines and therapeutics based on its next-generation self-amplifying RNA (saRNA) platform, […]
Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement of CyPep-1, a First-in-class Targeted Tumor Membrane Immunotherapy
Cytovation ASA, a clinical-stage immune-oncology company focused on the development of its first-in-class targeted tumor […]
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International and the INADcure Foundation, a nonprofit organization whose mission is to […]
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
Genmab has announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell […]
Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]
Sir Richard Roberts Elected to National Academy of Sciences
New England Biolabs (NEB®) has announced that Sir Richard Roberts, Nobel Prize winner and Chief […]